Journal of Clinical Oncology, Vol 23, No 14 (May 10), 2005: pp. 3219-3226
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.15.511
Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted Therapy
Matthew Meyerson,
David Carbone
From the Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and Vanderbilt Cancer Center, Nashville, TN
Address reprint requests to David P. Carbone, MD, PhD, Vanderbilt Cancer Center, 2220 Pierce Ave, 685 PRB, Nashville, TN 37232-6863; e-mail: d.carbone{at}Vanderbilt.edu.
Both proteomic and genomic methods offer promise for the classification of human lung carcinomas. This review summarizes the range of proteomic methods in development for lung cancer classification, and describes a number of recent analyses of messenger RNA expression in lung cancer. Multiple independent studies of mRNA expression profiles in lung adenocarcinoma have proven highly reproducible. Analyses of the relationship between expression profiles and tumor development and differentiation, the presence or absence of specific pathogenic mutations, patient prognosis and survival after surgical treatment, and specific histopathology all appear to be promising.
Authors' disclosures of potential conflicts of interest are found at the end of this article.
This article has been cited by other articles:

|
 |

|
 |
 
R. S. Herbst, J. V. Heymach, and S. M. Lippman
Lung Cancer
N. Engl. J. Med.,
September 25, 2008;
359(13):
1367 - 1380.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Seike, N. Yanaihara, E. D. Bowman, K. A. Zanetti, A. Budhu, K. Kumamoto, L. E. Mechanic, S. Matsumoto, J. Yokota, T. Shibata, et al.
Use of a Cytokine Gene Expression Signature in Lung Adenocarcinoma and the Surrounding Tissue as a Prognostic Classifier
J Natl Cancer Inst,
August 15, 2007;
99(16):
1257 - 1269.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. Elayadi, K. N. Samli, L. Prudkin, Y.-H. Liu, A. Bian, X.-J. Xie, I. I. Wistuba, J. A. Roth, M. J. McGuire, and K. C. Brown
A Peptide Selected by Biopanning Identifies the Integrin {alpha}v{beta}6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer
Cancer Res.,
June 15, 2007;
67(12):
5889 - 5895.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. W. Corson, C. Q. Zhu, S. K. Lau, F. A. Shepherd, M.-S. Tsao, and B. L. Gallie
KIF14 Messenger RNA Expression Is Independently Prognostic for Outcome in Lung Cancer
Clin. Cancer Res.,
June 1, 2007;
13(11):
3229 - 3234.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Potti, S. Mukherjee, R. Petersen, H. K. Dressman, A. Bild, J. Koontz, R. Kratzke, M. A. Watson, M. Kelley, G. S. Ginsburg, et al.
A Genomic Strategy to Refine Prognosis in Early-Stage Non-Small-Cell Lung Cancer
N. Engl. J. Med.,
August 10, 2006;
355(6):
570 - 580.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Raponi, Y. Zhang, J. Yu, G. Chen, G. Lee, J. M.G. Taylor, J. MacDonald, D. Thomas, C. Moskaluk, Y. Wang, et al.
Gene expression signatures for predicting prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res.,
August 1, 2006;
66(15):
7466 - 7472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. D. Petty, K. M. Kerr, G. I. Murray, M. C. Nicolson, P. H. Rooney, D. Bissett, and E. S.R. Collie-Duguid
Tumor Transcriptome Reveals the Predictive and Prognostic Impact of Lysosomal Protease Inhibitors in Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
April 10, 2006;
24(11):
1729 - 1744.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Takeuchi, S. Tomida, Y. Yatabe, T. Kosaka, H. Osada, K. Yanagisawa, T. Mitsudomi, and T. Takahashi
Expression Profile-Defined Classification of Lung Adenocarcinoma Shows Close Relationship With Underlying Major Genetic Changes and Clinicopathologic Behaviors
J. Clin. Oncol.,
April 10, 2006;
24(11):
1679 - 1688.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|